; Juniper Pharmaceuticals | Investor Relations Overview

Investor Relations Overview

Corporate Profile

Juniper Pharmaceuticals (Nasdaq: JNP) address unmet and underserved medical needs in women's health. Our product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:

  • JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
  • JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
  • JNP-0301, a natural progesterone IVR for the prevention of preterm birth.

Our R&D programs are supported by cash flow generated by Crinone® (progest  More >>

Stock Quote

JNP (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Down 0.05 (1.09%)
Data as of 03/28/17 11:21 a.m. ET
Minimum 20 minute delayRefresh quote
JNP Corporate Overview
Recent NewsMore >>
03/07/17Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating ResultsPrinter Friendly Version
03/06/17Juniper Pharmaceuticals to Present at ROTH Conference on March 14, 2017Printer Friendly Version
03/01/17Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2016 Results on March 7, 2017Printer Friendly Version
01/26/17Juniper Pharmaceuticals Presents Poster at SMFM 2017 on Current Practice Among U.S. Obstetricians to Screen, Define, and Treat a Short Cervix to Prevent Preterm BirthPrinter Friendly Version